Keywords
Tissue Plasminogen Activator
Tenecteplase
Mortality
Treatment Outcome
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To compare the efficacy of thrombolytic agents alteplase and tenecteplase on reducing mortality in patients diagnosed with acute ischemic stroke. Methods: This is a systematic literature review. The databases used for the search for randomized clinical trials published between 2012 and 2022 were Medical Publisher, Virtual Health Library, Science Direct and The Cochrane Central Register of Controlled Trials The Cochrane Library. Finally, the GRADE system was used to analyze the data obtained. Results: A total of 11 randomized controlled trials including 6370 patients with acute ischemic stroke were included. According to the GRADE classification, only four articles were classified as having high quality. Only one article made a direct comparison between tenecteplase and alteplase, including the analysis of mortality rates. However, by combining the results, this review showed lower mortality and complication rates and better imaging results and clinical efficacy in 24 hours and in the long term with the use of tenecteplase at a dose of 0.25 mg/kg. Final considerations: Tenecteplase at a dose of 0.25 mg/kg is an option to the medication alteplase for the treatment of the acute phase of stroke, as it generated lower mortality and complication rates.
References
ANDERSON CS, et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. The New England Journal of Medicine, 2016; 374(24): 2313-2323.
BERGE E, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European Stroke Journal, 2021; 6(1): 1-62.
BRASIL. Manual de Rotinas para Atenção ao AVC. 2013. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/manual_rotinas_para_atencao_avc.pdf. Acessado em: 10 de novembro de 2022.
BRASIL. Lei nº. 9.610, de 19 de fevereiro de 1998. Altera, atualiza e consolida a legislação sobre direitos autorais e dá outras providências. Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l9610.htm. Acessado em: 13 de outubro de 2022.
BRODERICK JP, et al. Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke. The New England Journal of Medicine, 2013; 368(10): 893-903.
CAMPOS DB, et al. Custo-efetividade de alteplase no tratamento de acidente vascular cerebral isquêmico até 4,5 horas após início dos sintomas: perspectiva do Sistema Único de Saúde do Brasil (SUS). Jornal brasileiro de economia da saúde, 2020; 12(3): 241-254.
CAMPBELL BCV, et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study. International Journal of Stroke, 2019, 15(5):1-6.
DONATO H e DONATO M. Etapas na Condução de uma Revisão Sistemática. Act Méd Port, 2019; 32(3): 227-235.
FONSECA AC, et al. European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. European Stroke Journal, 2021; 6(2): 1-24.
GALVÃO MCB e RICARTE, ILM. Revisão Sistemática da Literatura: Conceituação, Produção e Publicação. LOGEION: Filosofia da Informação, 2020; 6(1): 57-73.
JACINTO AFA e PEREZ FJA. AVC Isquémico: Impacto do Tratamento de Fase Aguda no Outcome Clínico. Repositório Digital da Universidade Beira Interior, 2021; 1-47.
KOGA M, et al. Thrombolysis With Alteplase at 0,6 mg/kg for Stroke With Unknown Time of Onset. Stroke, 2020; 51(5).
LANDIM MAC, et al. Barreiras que Atrasam o Uso da Terapia Trombolítica Em Pacientes Com AVCi Agudo em Emergência: Quais seus Impactos? Revista Corpus Hippocraticum, 2021; 2(1): 1-9.
LECOUFFE NE, et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. The New England Journal of Medicine, 2021; 385(20): 1833-1844.
MA H, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. The New England Journal of Medicine, 2019; 380(19): 1795-1803.
MOHER D, et al. Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde, 2015; 24(2): 335-342.
OLIVEIRA M, et al. Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis. The American Journal of Emergency Medicine, 2020; 42: 31-37.
ORGANIZAÇÃO MUNDIAL DA SAÚDE. The top 10 causes of death, 2020. Disponível em: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Acessado em: 24 out. 2022.
PAGE MJ, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Research Methods and Reporting, 2021; 372(160).
PARSONS M, et al. A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke. The New England Journal of Medicine, 2012; 366(12): 1099-1107.
POTLA N, GANTI L. Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review. International Journal of Emergency Medicine, 2022; 15(1): 1-6.
POWERS WJ, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke, 2019; 50(12): 344-418.
RENÚ A, et al. Effect of Intra-arterial Alteplase vc Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke. The Journal of The American Medical Association, 2022; 327(9): 826-835.
RODRIGUES SBL e PÉREZ FJA. Utilização de técnicas de imagem na seleção de pacientes candidatos a trombólise: Tratamento após 4.5 horas. Repositório Digital da Universidade Beira Interior, 2020; 1-48.
ROSÁRIO CF, et al. Epidemiological analysis of stroke patients with emphasis on access to acute-phase therapies. Arquivos de Neuro-Psiquiatria, 2022; 80(2): 1-8.
ROXA GN, et al. Perfil epidemiológico dos pacientes acometidos com AVC isquêmico submetidos a terapia trombolítica: uma revisão integrativa. Brazilian Journal of Development, 2021; 7(1): 7341-7351.
SARTORETTO ER, et al. Contraindicações ao Uso de Trombolítico em Pacientes Acometidos por Acidente Vascular Cerebral Isquêmico num Hospital De Alta Complexidade do Sul Catarinense no Período de 2012 a 2014. Arquivos Catarinenses de Medicina, 2019; 48(1): 108-117.
SILVA DN, et al. Cuidados de enfermagem à vítima de acidente vascular cerebral (AVC): Revisão integrativa. Revista Eletrônica Acervo Saúde, 2019; 36: e2136.
SZYMANSKI P, et al. Trombólise Endovenosa em Acidente Vascular Cerebral isquêmico: uma revisão de literatura. Revista Neurociências, 2021; 29: 1-16.
SAVER JL, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. The New England Journal of Medicine, 2015; 372(24): 2285-2295.
THELENGANA A, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurologica Belgica, 2019; 119: 359-367.
WENJI Z, et al. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. The Journal of the American Medical Association, 2021; 325(3): 234-243.
YANG P, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. The New England Journal of Medicine, 2020; 382(21): 1981-1993.